Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Are The Current (2025) And Forecast (2029) Sizes Of The Hereditary Transthyretin Amyloidosis Market?
The hereditary transthyretin amyloidosis market size has shown substantial growth in recent years. It is projected to increase from $1.36 billion in 2024 to $1.49 billion in 2025, achieving a compound annual growth rate (CAGR) of 9.3%. The expansion observed historically is attributed to the escalating incidence of this condition, a boost in research and development activities, an increasing prevalence of cardiac amyloidosis cases, heightened disease awareness, and the development of healthcare infrastructure.
The market size for hereditary transthyretin amyloidosis is anticipated to show robust expansion over the next few years. It is projected to reach $2.09 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.0%. The expansion during the forecast period is driven by an increasing geriatric population, higher disposable incomes, a rising incidence of hereditary transthyretin amyloidosis, an increase in new drug development, and a growth in genetic testing. Noteworthy trends for the forecast period include advanced treatment products, enhancements in diagnostic techniques, progress in drug development, a demand for effective therapies, and advancements in medical technology.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp
Which Major Market Drivers Are Shaping The Future Of The Hereditary Transthyretin Amyloidosis Market?
The market for hereditary transthyretin amyloidosis is anticipated to expand due to the increasing geriatric population. This demographic refers to individuals aged 65 and older, who frequently require specialized healthcare and support as they age. The expansion of the geriatric population stems from longer life expectancies, fueled by advancements in healthcare and improved living conditions. Hereditary transthyretin amyloidosis (hATTR) notably affects older adults by inducing progressive neuropathy and cardiomyopathy, thereby increasing health complications in aging individuals. For example, in January 2024, according to the US-based nonprofit Population Reference Bureau, the US population aged 65 and older is projected to grow from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Consequently, the expanding geriatric population is a key factor propelling the growth of the hereditary transthyretin amyloidosis market.
How Is The Hereditary Transthyretin Amyloidosis Market Classified Into Different Segments?
The hereditary transthyretin amyloidosismarket covered in this report is segmented –
1) By Type: Oral; Subcutaneous Injection; Other Types
2) By Drug Class: RNAi Agents (Patisiran); Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
4) By Application: Hospital; Clinic; Other Applications
Subsegments:
1) By Oral: Tafamidis; Diflunisal; Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran; Inotersen; Vutrisiran
3) By Other Types: Intravenous Therapies; Gene Silencing Therapies; CRISPR-Based Therapies
What Key Innovation Trends Are Fueling Advancements In The Hereditary Transthyretin Amyloidosis Market?
Leading companies in the hereditary transthyretin amyloidosis market are developing innovative treatments, such as RNAi therapeutics, aimed at targeting and lowering the production of the transthyretin (TTR) protein. These RNAi therapeutics represent a class of medications that utilize RNA interference technology to silence specific genes, thereby reducing the synthesis of disease-causing proteins. For instance, in October 2024, Alnylam Pharmaceuticals, Inc., a US-based biopharmaceutical firm, submitted a supplemental new drug application (sNDA) to the US FDA for Vutrisiran (AMVUTTRA) for the treatment of transthyretin amyloidosis with cardiomyopathy. This submission emphasizes its pioneering RNAi therapeutic strategy, specifically designed to target and diminish transthyretin (TTR) protein, a crucial factor in the progression of the disease. The subcutaneous administration of Vutrisiran offers a more convenient and patient-friendly dosing regimen compared to traditional intravenous treatments, positioning it as a potentially transformative choice for individuals living with this serious condition.
Who Are The Major Companies Operating In The Hereditary Transthyretin Amyloidosis Market?
Major companies operating in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, Autotac Bio Inc.
Download The Full Report For Exclusive Market Findings:
Which Region Is Projected To Lead The Hereditary Transthyretin Amyloidosis Market During The Forecast Period?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Hereditary Transthyretin Amyloidosis Market Report:
https://www.thebusinessresearchcompany.com/customise?id=22003&type=smp
Browse Through More Reports Similar to the Global Hereditary Transthyretin Amyloidosis Market 2025, By The Business Research Company
Hereditary Cancer Testing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report
Hereditary Angioedema Therapeutics Global Market Report 2025
Hereditary Breast And Ovarian Cancer Syndrome Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model